文献速递造血干细胞移植与细胞治疗血栓与止血

接受细胞治疗血液恶性肿瘤患者的粪菌移植:从转化研究到常规临床实践

Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice.
PubMed 文献 · Lancet Haematol · 2022-01-01

综述阐述肠道微生物群对异基因造血干细胞移植(HCT)后结局的影响已明确,菌群失调与急性移植物抗宿主病(GVHD)相关,并可能影响自体HCT和CAR T细胞治疗结局。粪菌移植已被评估用于艰难梭菌感染、多重耐药菌清除和类固醇难治性急性GVHD等适应证,预防性粪菌移植正在异基因HCT中发展,并可能很快用于自体HCT或CAR T细胞患者。

要点

  • 肠道菌群失调与异基因HCT后急性GVHD相关。
  • 粪菌移植已评估用于艰难梭菌感染、多重耐药菌清除和类固醇难治性急性GVHD。
  • 预防性粪菌移植正在异基因HCT中发展,可能很快用于自体HCT或CAR T细胞患者。

核心结论

  • 肠道微生物群对异基因HCT后患者结局的影响已明确,菌群失调与急性GVHD相关。
  • 粪菌移植已在血液恶性肿瘤患者中针对多种适应证进行评估,预防性粪菌移植正在异基因HCT中发展,并可能很快用于自体HCT或CAR T细胞患者。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 肠道菌群失调与急性GVHD相关。
  • 越来越多的数据也提示肠道微生物群影响自体HCT和CAR T细胞治疗后的结局。
  • 细菌性肠道微生物群与免疫系统相互作用,参与免疫并发症和对治疗的抗肿瘤反应。

临床怎么用

  • 粪菌移植已在血液恶性肿瘤患者中用于艰难梭菌感染、多重耐药菌清除和类固醇难治性急性GVHD等适应证。
  • 预防性粪菌移植用于恢复肠道微生物群和改善患者结局正在异基因HCT中发展,并可能很快用于自体HCT或CAR T细胞患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The effect of the gut microbiota on patients' outcomes after allogeneic haematopoietic cell transplantation (HCT) is now well established. In particular, gut microbiota dysbiosis has been associated with acute graft-versus-host disease (GVHD). Furthermore, increasing data also suggest an effect of the gut microbiota on outcome after autologous HCT and CAR T cells. In fact, the bacterial gut microbiota interplays with the immune system and contributes to immunological complication and antitumour response to treatment. Therefore, faecal microbiota transplantation has been evaluated in patients with haematological malignancies for various indications, including Clostridioides difficile infection, eradication of multidrug-resistant bacteria, and steroid refractory acute GVHD. In addition, use of prophylactic faecal microbiota transplantation to restore the gut microbiota and improve patients' outcomes is being developed in the setting of allogeneic HCT, but also probably very soon in patients receiving autologous HCT or CAR T cells.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Malard F, Gaugler B, Mohty M, et al. Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice. Lancet Haematol. 2022. PMID: 36174640. doi:10.1016/S2352-3026(22)00223-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。